According to the announcement issued by BioCubafarma authorities, and after the approval of the State Center for the Control of Medicines and Medical Devices, this new trial modality will be launched in order to expand the population sample and the effects against Covid-19.
Workers of the health and biopharmaceutical system will be the first to take part in this test, followed by people from the most diverse sectors of the population in an ever-growing universe of individuals interested and motivated to take part in a successful experiment.
In these three cities in the eastern region of the country, the third phase of clinical trials of the antigen formula, created in the laboratories of the Center for Genetic Engineering and Biotechnology and as part of the efforts of Cuban science that includes four other candidates against the pandemic since last March 22.
A total of 48,000 volunteers will be inoculated with Abdala, which has already reached more than 40 percent of this stage, with about 19,524 people from Santiago, Guantanamo and Bayamo having received the vaccine.
The name of the vaccine, in allusion to the dramatic poem of the same name by Jose Marti, is a source of inspiration for the participants, together with the proven safety and immunogenicity indexes demonstrated in phases one and two that took place in this city since last December.